相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Age-Related Decline in Primary CD8+ T Cell Responses Is Associated with the Development of Senescence in Virtual Memory CD8+ T Cells
Kylie M. Quinn et al.
CELL REPORTS (2018)
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Alex M. Abel et al.
FRONTIERS IN IMMUNOLOGY (2018)
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
M. Ilander et al.
LEUKEMIA (2017)
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Delphine Rea et al.
HAEMATOLOGICA (2017)
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML
C. Schuetz et al.
LEUKEMIA (2017)
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study
Delphine Rea et al.
HAEMATOLOGICA (2017)
The Hypothesis of the Human inKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia
Florence Jacomet et al.
FRONTIERS IN IMMUNOLOGY (2017)
Evidence for eomesodermin-expressing innate-like CD8+ KIR/NKG2A+ T cells in human adults and cord blood samples
Florence Jacomet et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
Lisa Christiansson et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Type I interferons regulate eomesodermin expression and the development of unconventional memory CD8+ T cells
Valerie Martinet et al.
NATURE COMMUNICATIONS (2015)
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
Jun Imagawa et al.
LANCET HAEMATOLOGY (2015)
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice
Ci-U Chen et al.
LEUKEMIA (2012)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
T cells expressing the transcription factor PLZF regulate the development of memory-like CD8+ T cells
Michael A. Weinreich et al.
NATURE IMMUNOLOGY (2010)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
